{
    "clinical_study": {
        "@rank": "114314", 
        "arm_group": [
            {
                "arm_group_label": "20 mg LY3015014 Q4W", 
                "arm_group_type": "Experimental", 
                "description": "20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }, 
            {
                "arm_group_label": "120 mg LY3015014 Q4W", 
                "arm_group_type": "Experimental", 
                "description": "120 mg LY3015014 given SC Q4W for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }, 
            {
                "arm_group_label": "300 mg LY3015014 Q4W", 
                "arm_group_type": "Experimental", 
                "description": "300 mg LY3015014 given SC Q4W for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }, 
            {
                "arm_group_label": "100 mg LY3015014 Q8W", 
                "arm_group_type": "Experimental", 
                "description": "100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }, 
            {
                "arm_group_label": "300 mg LY3015014 Q8W", 
                "arm_group_type": "Experimental", 
                "description": "300 mg LY3015014 given SC Q8W for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }, 
            {
                "arm_group_label": "Placebo Q4W", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo given SC Q4W for 16 weeks.\nParticipants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to define the amount and duration of cholesterol lowering and to\n      assess the safety and tolerability of different dose regimens of LY3015014 in participants\n      with high cholesterol. The study will also investigate how the body processes the drug and\n      how the drug affects the body. Participants will remain on a stable diet and will continue\n      taking cholesterol-lowering medications (statins with or without ezetimibe). After signing\n      the informed consent document, the participant will complete a screening/run-in period that\n      will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks.\n      After the treatment period, the participants will complete a  follow-up period lasting\n      approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks."
        }, 
        "brief_title": "A Study of LY3015014 in Participants With High Cholesterol", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with high low density lipoprotein (LDL) cholesterol\n\n          -  Are on stable daily dose of a statin or have a history of statin intolerance\n\n          -  Men with a partner who can become pregnant must agree to use barrier protection\n             during sexual intercourse to prevent pregnancies\n\n          -  Women who cannot become pregnant, or women who are not pregnant or breast feeding and\n             agree to use a reliable method of birth control to prevent pregnancies\n\n        Exclusion Criteria:\n\n          -  Have high cholesterol due to another disease or have a rare and serious form of\n             hereditary high cholesterol\n\n          -  Have had recent heart attack, stroke, blood clot or heart surgery,  have planned\n             heart or blood vessel surgery, or has a heart that does not pump sufficiently well\n\n          -  Have poorly controlled high blood pressure\n\n          -  Have diabetes that requires an injectable medication (including insulin), or have\n             diabetes that is poorly controlled\n\n          -  Have thyroid blood test that is outside normal range\n\n          -  Have a history of adrenal gland disorder\n\n          -  Have a history of vitamin E deficiency or fat malabsorption syndrome\n\n          -  Have poor kidney function\n\n          -  Have active liver or gall bladder disease, history of hepatitis or liver blood tests\n             that are  high\n\n          -  Have a history of  muscle disease including muscle damage from a medicine or muscle\n             blood test  that is high\n\n          -  Are anemic (low red blood cell counts)\n\n          -  Have a history of allergy or intolerance to other antibody medications\n\n          -  Have a history of human immunodeficiency virus infection (HIV) infection\n\n          -  Are likely to have a major operation or be hospitalized during the study\n\n          -  Have chronic alcohol or drug abuse or dependency\n\n          -  Have or suspected to have any cancer or malignant tumor\n\n          -  Have an active serious infection\n\n          -  Have started or stopped taking a statin or ezetimibe medication, or changed statin\n             dose regimen recently\n\n          -  Are on a statin regimen other than daily dosing (for example, an every-other-day\n             statin regimen)\n\n          -  Have recently used simvastatin (highest dose level), fibrates, bile acid binders,\n             niacin, probucol, or over-the-counter/health food preparations to lower cholesterol\n             (such as red yeast rice, fish oil, omega 3 fatty acid)\n\n          -  Have undergone LDL apheresis in the past 1 year\n\n          -  Have recently used steroids, cyclosporine or isotretinoin\n\n          -  Have recently used an immunosuppressive therapy\n\n          -  Have recently received treatment with another antibody medication\n\n          -  Are currently using medications injected into the skin , except for single injections\n             (for example flu vaccines) or injections into muscles\n\n          -  Are currently on a prescription or over-the-counter medicine for weight loss or are\n             on a very low carbohydrate diet"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "528", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890967", 
            "org_study_id": "14853", 
            "secondary_id": "I5S-MC-EFJE"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "20 mg LY3015014 Q4W", 
                    "120 mg LY3015014 Q4W", 
                    "300 mg LY3015014 Q4W", 
                    "100 mg LY3015014 Q8W", 
                    "300 mg LY3015014 Q8W"
                ], 
                "description": "Administered SC", 
                "intervention_name": "LY3015014", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Q4W", 
                "description": "Administered SC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia", 
        "lastchanged_date": "February 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encino", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91436"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lancaster", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93534"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spring Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91978"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Safety Harbor", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34695"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33613"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46290"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40213"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bossier", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "71111"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28205"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27609"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45227"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43615"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamloops", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V2C 1K7"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kelowna", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V1Y3G5"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brampton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L6T 0G1"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5K8c"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4G 3E8"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gatineau", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J8Y 6S8"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H1T 1C8"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Marc Des Carrieres", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G0A 4B0"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cesky Krumlov", 
                        "country": "Czech Republic", 
                        "zip": "381 01"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hodonin", 
                        "country": "Czech Republic", 
                        "zip": "695 01"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "150 06"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Svitavy", 
                        "country": "Czech Republic", 
                        "zip": "568 25"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "DK-9000"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100 CPH"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark", 
                        "zip": "6700"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hellerup", 
                        "country": "Denmark", 
                        "zip": "2900"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hvidovre", 
                        "country": "Denmark", 
                        "zip": "2650"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "819-0375"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-0001"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "171-0033"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands", 
                        "zip": "4811 SW"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goes", 
                        "country": "Netherlands", 
                        "zip": "4462 RA"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9711 SG"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6229 HX"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "6525 HB"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3021 HC"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-351"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland", 
                        "zip": "80-546"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "30-015"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lodz", 
                        "country": "Poland", 
                        "zip": "90-242"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-582"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ponce", 
                        "country": "Puerto Rico", 
                        "zip": "00717-1322"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "Japan", 
                "Netherlands", 
                "Poland", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Ethics Committee", 
                "Denmark: Danish Health and Medicines Authority", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890967"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage Change from Baseline in Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C,  Apolipoprotein B (Apo B), Apolipoprotein A-1 (Apo A-1), Lipoprotein(a) (Lp[a])", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Change from Baseline in high sensitivity C-Reactive Protein (hsCRP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Percentage of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Baseline through Week 24"
            }, 
            {
                "measure": "Percentage Change from Baseline in Total and Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 16"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) at Steady-State for LY3015014", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through Week 16"
            }, 
            {
                "measure": "Percentage of Participants with an Injection Site Reaction", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through Week 24"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}